Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (TheStreet) -- CHANGE IN RATINGS
Biogen Idec (BIIB) upgraded at RBC from Sector Perform to Outperform, RBC Capital said. $75 price target. New analyst expects Tysabri to perform above consensus expectations.
Celgene (CELG) downgraded at RBC from Outperform to Sector Perform, RBC Capital said. $55 price target. Valuation call, as the stock is already pricing in solid 2011 growth.Chesapeake Energy (CHK) upgraded at Canaccord from Hold to Buy, Canaccord Genuity said. $49 price target. Company is improving capital productivity and realizing higher gas prices. Ciena (CIEN) rated new Outperform at Wells Fargo. Company is leveraged to a multi-year optical upgrade cycle. Celestica (CLS) upgraded at Collins Stewart from Neutral to Buy, Collins Stewart said. $15 price target. Company is turning its business around and winning new customers. Flextronics (FLEX) upgraded at Collins Stewart from Neutral to Buy, Collins Stewart said. $11 price target. Company can deliver double-digit growth in each of the next two years. Fluor (FLR) upgraded at BMO from Underperform to Market Perform, BMO Capital said. $66 price target. Company has a solid balance sheet, and can absorb losses from two fixed-price contracts. Netease.com (NTES) upgraded at Brean Murray from Hold to Buy, Brean Murray said. $54 price target. Company is seeing higher demand across the board. Ormat Technologies (ORA) downgraded at Baird to Neutral from Outperform, Robert Baird said. $24 price target. Company lowered its guidance, because of rising costs. Oracle (ORCL) rated new Hold at ThinkEquity. $35 price target. Stock is already pricing in solid near-term growth. Quanta Services (PWR) downgraded at Deutsche Bank to Hold. $22 price target. Valuation call, as the stock is up 26% over the past three months. Regeneron Pharmaceuticals (REGN) upgraded at RBC from Sector Perform to Outperform, RBC Capital said. $48 price target. Company continues to price solid clinical data. Red Hat (RHT) downgraded at JP Morgan from Neutral to Underweight. $32 price target. Valuation call, as the stock is already pricing in healthy free cash flow growth.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV